Antibody drug discovery — starting from target identification & generation, lead validation & optimizations, preclinical candidate selection to clinical phases — is an arduous and challenging process. Advanced antibody discovery platforms and innovative techniques for antibody functional screening contribute to accelerating and improving the success rates in current therapeutics development. Once the drug candidate is identified, stringent efficacy and safety evaluations are essential from preclinical to clinical stage. An anti-idiotypic antibody is capable of binding to antibody drugs within biological fluids, therefore they are commonly used to validate drug efficacy through pharmacokinetics and pharmacodynamics kinetic assays and also used to evaluate drug safety by measuring the antibody drug immunogenicity through anti-drug antibody assays.

In this webinar, the featured speaker will discuss:

An overview of anti-idiotypic antibodies in antibody drug discovery
Overcoming the timeline challenges in antibody drug discovery with anti-idiotypic antibody platforms
Elaborate on successful case studies in current popular therapeutics such as antibody drug conjugates, single-chain variable fragments (scFv), VHH antibody, bi-specific antibody, etc.
Strategies and advantages of anti-drug antibody assays and pharmacokinetic ELISA kit development

Join this webinar to learn how anti-idiotypic antibody platforms accelerate drug discovery.

Keywords:

Speaker

Hui Foon Tan, Global Product Manager, GenScript

Hui Foon Tan is a Global Product Manager who supports GenScript antibody production service currently. She graduated with her PhD in biological sciences from Nanyang Technological University, Singapore and continued to work as a Postdoctoral Research Fellow in cancer research for another two years. After joining GenScript, Dr. Tan supported proteins and antibody production services in the APAC region for a year. She now provides application support for pre- and post-sale activities for services, updates and seminars to support co-stakeholders, distributors and customers. Currently, she is supporting new services launching and training in antibody production services. She also collates market dynamics and competitive market information from the field to understand the global market trends and collaborate with the team.

Message Presenter

Who Should Attend?

Companies/Research Labs/Institutions working with:

Preclinical research and antibody discovery and development
Pharmacokinetic/pharmacodynamics studies and immunogenicity assays
Vaccine development
Antibody Sequencing/Engineering/Production
Target discovery/screening

What You Will Learn

Attendees will discover:

An overview of anti-idiotypic antibodies in antibody drug discovery
How to overcome the timeline challenges in antibody drug discovery with anti-idiotypic antibody platforms
Successful case studies in current popular therapeutics such as antibody drug conjugates, single-chain variable fragments (scFv), VHH antibody, bi-specific antibody, etc.
Strategies and advantages of anti-drug antibody assays and pharmacokinetic ELISA kit development

Xtalks Partner

GenScript

GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody services. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.